Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.43
CCEL's Cash-to-Debt is ranked lower than
52% of the 266 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. CCEL: 0.43 )
Ranked among companies with meaningful Cash-to-Debt only.
CCEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: No Debt Max: No Debt
Current: 0.43
Equity-to-Asset -0.76
CCEL's Equity-to-Asset is ranked lower than
98% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. CCEL: -0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
CCEL' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.05  Med: -0.13 Max: 0.92
Current: -0.76
-1.05
0.92
Interest Coverage 1.42
CCEL's Interest Coverage is ranked lower than
91% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 8.41 vs. CCEL: 1.42 )
Ranked among companies with meaningful Interest Coverage only.
CCEL' s Interest Coverage Range Over the Past 10 Years
Min: 0.46  Med: 1.92 Max: 2.6
Current: 1.42
0.46
2.6
Piotroski F-Score: 4
Altman Z-Score: -0.19
Beneish M-Score: -3.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 5.86
CCEL's Operating Margin % is ranked lower than
56% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 7.39 vs. CCEL: 5.86 )
Ranked among companies with meaningful Operating Margin % only.
CCEL' s Operating Margin % Range Over the Past 10 Years
Min: -26.76  Med: 5.43 Max: 18.83
Current: 5.86
-26.76
18.83
Net Margin % -2.99
CCEL's Net Margin % is ranked lower than
81% of the 268 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. CCEL: -2.99 )
Ranked among companies with meaningful Net Margin % only.
CCEL' s Net Margin % Range Over the Past 10 Years
Min: -35.1  Med: -2.03 Max: 38.43
Current: -2.99
-35.1
38.43
ROA % -3.69
CCEL's ROA % is ranked lower than
82% of the 270 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. CCEL: -3.69 )
Ranked among companies with meaningful ROA % only.
CCEL' s ROA % Range Over the Past 10 Years
Min: -39.68  Med: -3.05 Max: 54.57
Current: -3.69
-39.68
54.57
ROC (Joel Greenblatt) % -60.60
CCEL's ROC (Joel Greenblatt) % is ranked lower than
91% of the 270 Companies
in the Global Medical Care industry.

( Industry Median: 16.38 vs. CCEL: -60.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CCEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -240.91  Med: 72.3 Max: 245.96
Current: -60.6
-240.91
245.96
3-Year Revenue Growth Rate 18.10
CCEL's 3-Year Revenue Growth Rate is ranked higher than
81% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. CCEL: 18.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CCEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18  Med: 12.1 Max: 97.8
Current: 18.1
-18
97.8
GuruFocus has detected 4 Warning Signs with Cryo-Cell International Inc $CCEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CCEL's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621999    SIC: 8099
Compare:OTCPK:FCHS, NAS:JYNT, OTCPK:ADPTQ, OTCPK:CVHIF, OTCPK:AMEH, OTCPK:BICX, AMEX:AMS, OTCPK:MIHI, OTCPK:JRSS, OTCPK:HPHW, NAS:CATS, AMEX:SSY, OTCPK:BNKL, OTCPK:ARPC, OTCPK:CAMDF, OTCPK:PFHO, OTCPK:AGHEF, OTCPK:LMNK, OTCPK:WNDM, OTCPK:GRST » details
Headquarter Location:USA
Cryo-Cell International Inc is engaged in cellular processing & cryogenic storage. Its services include umbilical cord blood banking, umbilical cord tissue banking and umbilical cord blood & tissue banking prices.

Cryo-Cell International, Inc. was incorporated on September 11, 1989 in the State of Delaware. The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord9(r)) blood stem cells for family use. The Company has established private family cord blood stem cell banks in terms of the number of specimens preserved. Its headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations, including the processing and storage of specimens. The specimens are stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Oldsmar, Florida. It has expanded its research and development activities to develop technologies related to stem cells other than umbilical cord blood stem cells. During 2006, in parallel with its R&D associated with placental stem cells, the Company discovered novel technology related to menstrual stem cells. In November 2007, the Company announced the launch of its C'elleSM service related to this patent-pending technology, and the Company continues to focus its current research and development activities mainly on the C'elle service and related new menstrual stem cell technologies. The Company is actively marketing the C'elle service both through a bundled offer with the Company's U-Cord service and on a stand-alone basis. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, Lamaze instructors and other childbirth educators, certified nurse-midwives and other related healthcare professionals. To increase awareness among expectant parent audiences, the Company continues to promote its service in several national targeted prenatal magazines including American Baby and Fit Pregnancy, as well as several magazines distributed during childbirth classes. Expectant parents have also received information via emails and the Company has increased its internet marketing campaigns. Its competitors are Cord Blood Registry, Inc., ViaCord, a division of ViaCell, Inc., a wholly-owned subsidiary of PerkinElmer and LifeBankUSA, a division of Celgene. The Company is required to register with the FDA under the Public Health Service Act.

Top Ranked Articles about Cryo-Cell International Inc

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2017 Financial Results
Cryo-Cell Reports Financial Results for Fiscal 2016

OLDSMAR, Fla., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year 2016.  
Financial Results Revenue Consolidated revenues for fiscal 2016 were approximately $23.1 million compared to approximately $21.1 million for fiscal 2015.  The revenues for fiscal 2016 consisted of approximately $21.8 million in processing and storage fee revenue, $1.0 million in licensee income, and $350,000 in product revenue compared to approximately $19.6 million in processing and storage fee revenue, approximately $1.0 million in licensee income and $471,000 in product revenue for fiscal 2015.  Net (Loss) Income The Company reported a net loss in fiscal 2016 of ($1.3) million, or ($0.16) per basic share, compared to net income of $8.1 million, or $0.85 per basic share and $0.83 per diluted share, in fiscal 2015.  The net loss in fiscal 2016 resulted from the cancellation of certain interests in the Florida Revenue Sharing Agreement and certain interests in the Texas Revenue Sharing Agreement resulting in loss on extinguishment of revenue sharing agreements in the amount of $2.3 million, goodwill and intangible assets impairment of $2.0 million, a 19% increase in selling, general and administrative expenses and a 3% increase in cost of sales.  This was offset by a 10% increase in total revenue and an income tax benefit of approximately $1,159,000.  During fiscal 2015, the Company released approximately $8.2 million of its valuation allowance for income taxes.  Cash and Cash Equivalent Position
           
As of November 30, 2016, the Company had cash and cash equivalents of $3.5 million.  The Company’s cash decreased by approximately $652,000 during fiscal 2016, primarily as a result of approximately $10.8 million used for stock repurchases offset by cash flow from operations of approximately $5.0 million and an increase in total debt to approximately $10.2 million.  About Cryo-Cell International, Inc. Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank.  More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells.  Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com.  Forward-Looking Statement Statements wherein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.
Contact:

David Portnoy
Cryo-Cell International, Inc.
813-749-2100
[email protected]


Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 52.80
CCEL's Price-to-Owner-Earnings is ranked lower than
74% of the 107 Companies
in the Global Medical Care industry.

( Industry Median: 27.27 vs. CCEL: 52.80 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CCEL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.55  Med: 10.72 Max: 109.78
Current: 52.8
2.55
109.78
PS Ratio 2.02
CCEL's PS Ratio is ranked lower than
56% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 1.71 vs. CCEL: 2.02 )
Ranked among companies with meaningful PS Ratio only.
CCEL' s PS Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.33 Max: 2.35
Current: 2.02
0.28
2.35
Price-to-Free-Cash-Flow 9.26
CCEL's Price-to-Free-Cash-Flow is ranked higher than
88% of the 117 Companies
in the Global Medical Care industry.

( Industry Median: 24.29 vs. CCEL: 9.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CCEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.05  Med: 13.38 Max: 218.46
Current: 9.26
4.05
218.46
Price-to-Operating-Cash-Flow 8.80
CCEL's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 169 Companies
in the Global Medical Care industry.

( Industry Median: 15.22 vs. CCEL: 8.80 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CCEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.33  Med: 11.63 Max: 277
Current: 8.8
3.33
277
Current Ratio 0.74
CCEL's Current Ratio is ranked lower than
80% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. CCEL: 0.74 )
Ranked among companies with meaningful Current Ratio only.
CCEL' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.37 Max: 35.3
Current: 0.74
0.47
35.3
Quick Ratio 0.72
CCEL's Quick Ratio is ranked lower than
77% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. CCEL: 0.72 )
Ranked among companies with meaningful Quick Ratio only.
CCEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.37 Max: 35.3
Current: 0.72
0.47
35.3
Days Inventory 24.78
CCEL's Days Inventory is ranked lower than
62% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 15.65 vs. CCEL: 24.78 )
Ranked among companies with meaningful Days Inventory only.
CCEL' s Days Inventory Range Over the Past 10 Years
Min: 2.07  Med: 17.5 Max: 26.45
Current: 24.78
2.07
26.45
Days Sales Outstanding 68.38
CCEL's Days Sales Outstanding is ranked lower than
80% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 41.13 vs. CCEL: 68.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.43  Med: 55.27 Max: 73.85
Current: 68.38
46.43
73.85
Days Payable 93.37
CCEL's Days Payable is ranked higher than
68% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 45.04 vs. CCEL: 93.37 )
Ranked among companies with meaningful Days Payable only.
CCEL' s Days Payable Range Over the Past 10 Years
Min: 49.91  Med: 84.36 Max: 104.76
Current: 93.37
49.91
104.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 14.20
CCEL's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: -2.40 vs. CCEL: 14.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -0.4 Max: 14.2
Current: 14.2
-14.9
14.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 6.17
CCEL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
94% of the 98 Companies
in the Global Medical Care industry.

( Industry Median: 1.95 vs. CCEL: 6.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CCEL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.46  Med: 7.19 Max: 90
Current: 6.17
2.46
90
Price-to-Median-PS-Value 1.51
CCEL's Price-to-Median-PS-Value is ranked lower than
76% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 1.06 vs. CCEL: 1.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CCEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.23 Max: 67.6
Current: 1.51
0.3
67.6
Earnings Yield (Greenblatt) % -1.17
CCEL's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 270 Companies
in the Global Medical Care industry.

( Industry Median: 3.82 vs. CCEL: -1.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CCEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.3  Med: 3.3 Max: 642.2
Current: -1.17
-95.3
642.2

More Statistics

Revenue (TTM) (Mil) $23.75
EPS (TTM) $ -0.12
Beta-0.45
Short Percentage of Float0.17%
52-Week Range $3.07 - 5.99
Shares Outstanding (Mil)7.15

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}